 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Inhaled Iloprost to Treat Severe Pulmonary Hypertension
21 March 2000 | Volume 132 Issue 6 | Page 435
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Inhaled Iloprost To Treat Severe Pulmonary Hypertension. An Uncontrolled Trial.". It is in the 21 March 2000 issue of Annals of Internal Medicine (volume 132, pages 435-443). The authors are H. Olschewski, H.A. Ghofrani, T. Schmehl, J. Winkler, H. Wilkens, M.M. Höper, J. Behr, F.-X. Kleber, and W. Seeger, for the German PPH Study Group.
What is the problem and what is known about it so far?
Pulmonary hypertension (high blood pressure in the arteries that go to the lungs) can produce disabling shortness of breath and often causes death. It can occur on its own (primary pulmonary hypertension) but is usually the result of an underlying lung disease, such as scleroderma (secondary pulmonary hypertension). No proven therapies for pulmonary hypertension are known, but the drug prostacyclin has shown some promise in patients with this condition. Unfortunately, the side effects of prostacyclin and the need to give it intravenously limit its usefulness. Aerosolized iloprost is a form of prostacyclin that patients can inhale. Reports on a few patients have suggested improvement in patients with pulmonary hypertension after they inhaled iloprost.
Why did the researchers do this particular study?
They wanted to find out whether inhaled iloprost might really offer benefit as therapy for patients with severe pulmonary hypertension.
Who was studied?
Nineteen patients with primary or secondary pulmonary hypertension who were doing poorly despite maximum usual therapy. Patients were cared for at six German teaching hospitals.
How was the study done?
All 19 patients inhaled iloprost 6 to 12 times daily for 3 months. The researchers measured the degree to which shortness of breath limited patients' activities by observing how far patients could walk in 6 minutes, both at the beginning of the study and again after 3 months of treatment. They also performed special tests of blood flow to the lungs and heart function by inserting catheters into the patients' lung vessels.
What did the researchers find?
Only 12 of the 19 patients had the special catheter tests; only 8 patients completed the 6-minute walk test at baseline, and 9 completed that test after 3 months of treatment. The tests of heart function showed improvement after 3 months. The distance patients could walk in 6 minutes improved an average of 148 meters, an increase of nearly 100% compared to how far they could walk before treatment. Four patients died before completing 3 months of treatment. Of the remaining 15 patients, 8 stopped taking iloprost after about 1 year because they got lung transplants, 1 patient switched to intravenous prostacyclin, and another 3 died after the end of the 3-month study period. Seven patients continued to receive iloprost at the time that the researchers completed this report.
What were the limitations of the study?
The study did not include a control group of patients who received only usual therapy. Therefore, although study patients appeared to improve with inhaled iloprost, it is uncertain whether they did significantly better than patients who received only usual therapy would have done.
What are the implications of the study?
Inhaled iloprost may offer a new treatment option for people with pulmonary hypertension. However, larger studies with control groups are needed.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  Y.-J. Lai, S. S. Pullamsetti, E. Dony, N. Weissmann, G. Butrous, G.-A. Banat, H. A. Ghofrani, W. Seeger, F. Grimminger, and R. T. Schermuly Role of the Prostanoid EP4 Receptor in Iloprost-mediated Vasodilatation in Pulmonary Hypertension Am. J. Respir. Crit. Care Med., July 15, 2008; 178(2): 188 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gomberg-Maitland and H. Olschewski Prostacyclin therapies for the treatment of pulmonary arterial hypertension Eur. Respir. J., April 1, 2008; 31(4): 891 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Heart, March 1, 2008; 94(Suppl_1): i1 - i41. [Full Text] [PDF]
|
|
|
|
 |
|
 National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Thorax, March 1, 2008; 63(Suppl_2): ii1 - ii41. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Pizanis, V. Milekhin, K. Tsagakis, I. Aleksic, M. Kamler, and H. Jakob PDE-5 inhibitor donor intravenous preconditioning is superior to supplementation in standard preservation solution in experimental lung transplantation Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 42 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Stitham, S. R. Gleim, K. Douville, E. Arehart, and J. Hwa Versatility and Differential Roles of Cysteine Residues in Human Prostacyclin Receptor Structure and Function J. Biol. Chem., December 1, 2006; 281(48): 37227 - 37236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. V. McLaughlin, R. J. Oudiz, A. Frost, V. F. Tapson, S. Murali, R. N. Channick, D. B. Badesch, R. J. Barst, H. H. Hsu, and L. J. Rubin Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., December 1, 2006; 174(11): 1257 - 1263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Ghofrani, R. Voswinckel, F. Reichenberger, N. Weissmann, R. T. Schermuly, W. Seeger, and F. Grimminger Hypoxia- and non-hypoxia-related pulmonary hypertension - Established and new therapies Cardiovasc Res, October 1, 2006; 72(1): 30 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Badesch, S. H. Abman, G. S. Ahearn, R. J. Barst, D. C. McCrory, G. Simonneau, and V. V. McLaughlin Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 35S - 62S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Badesch, V. V. McLaughlin, M. Delcroix, C. Vizza, H. Olschewski, O. Sitbon, and R. J. Barst Prostanoid therapy for pulmonary arterial hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 56S - 61S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Ghofrani, J. Pepke-Zaba, J. A. Barbera, R. Channick, A. M. Keogh, M. A. Gomez-Sanchez, M. Kneussl, and F. Grimminger Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 68S - 72S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Ghofrani, F. Rose, R. T. Schermuly, H. Olschewski, R. Wiedemann, A. Kreckel, N. Weissmann, S. Ghofrani, B. Enke, W. Seeger, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension J. Am. Coll. Cardiol., July 2, 2003; 42(1): 158 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wilkens, M. Bauer, N. Forestier, J. Konig, A. Eichler, S. Schneider, H.J. Schafers, and G.W. Sybrecht Influence of Inhaled Iloprost on Transpulmonary Gradient of Big Endothelin in Patients With Pulmonary Hypertension Circulation, March 25, 2003; 107(11): 1509 - 1513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.F Opitz, R Wensel, M Bettmann, R Schaffarczyk, M Linscheid, R Hetzer, and R Ewert Assessment of the vasodilator response in primary pulmonary hypertension: Comparing prostacyclin and iloprost administered by either infusion or inhalation Eur. Heart J., February 2, 2003; 24(4): 356 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Stitham, A. Stojanovic, B. L. Merenick, K. A. O'Hara, and J. Hwa The Unique Ligand-binding Pocket for the Human Prostacyclin Receptor. SITE-DIRECTED MUTAGENESIS AND MOLECULAR MODELING J. Biol. Chem., January 31, 2003; 278(6): 4250 - 4257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Schermuly, A. Schulz, H. A. Ghofrani, A. Meidow, F. Rose, A. Roehl, N. Weissmann, M. Hildebrand, J. Kurz, F. Grimminger, et al. Pharmacokinetics and Metabolism of Infused versus Inhaled Iloprost in Isolated Rabbit Lungs J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 741 - 745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Theodoraki, P. Rellia, A. Thanopoulos, L. Tsourelis, D. Zarkalis, P. Sfyrakis, and T. Antoniou Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass: [L'inhalation d'iloprost permet de controler l'hypertension pulmonaire apres la circulation extracorporelle] Can J Anesth, November 1, 2002; 49(9): 963 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Olschewski, G. Simonneau, N. Galie, T. Higenbottam, R. Naeije, L. J. Rubin, S. Nikkho, R. Speich, M. M. Hoeper, J. Behr, et al. Inhaled Iloprost for Severe Pulmonary Hypertension N. Engl. J. Med., August 1, 2002; 347(5): 322 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Stitham, A. Stojanovic, and J. Hwa Impaired Receptor Binding and Activation Associated with a Human Prostacyclin Receptor Polymorphism J. Biol. Chem., May 3, 2002; 277(18): 15439 - 15444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. C. Blumberg, G. A. J. Riegger, and M. Pfeifer Hemodynamic Effects of Aerosolized Iloprost in Pulmonary Hypertension at Rest and During Exercise* Chest, May 1, 2002; 121(5): 1566 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper, N. Galie, G. Simonneau, and L. J. Rubin New Treatments for Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., May 1, 2002; 165(9): 1209 - 1216. [Full Text] [PDF]
|
|
|
|
|
|
C D Vizza, S Sciomer, S Morelli, C Lavalle, P Di Marzio, D Padovani, R Badagliacca, A R Vestri, R Naeije, and F Fedele Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue Heart, December 1, 2001; 86(6): 661 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. SCHERMULY, E. KRUPNIK, H. TENOR, C. SCHUDT, N. WEISSMANN, F. ROSE, F. GRIMMINGER, W. SEEGER, D. WALMRATH, and H. A. GHOFRANI Coaerosolization of Phosphodiesterase Inhibitors Markedly Enhances the Pulmonary Vasodilatory Response to Inhaled Iloprost in Experimental Pulmonary Hypertension . Maintenance of Lung Selectivity Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1694 - 1700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wiedemann, H. A. Ghofrani, N. Weissmann, R. Schermuly, K. Quanz, F. Grimminger, W. Seeger, and H. Olschewski Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension: Response to iloprost inhalation J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1130 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wilkens, A. Guth, J. Konig, N. Forestier, B. Cremers, B. Hennen, M. Bohm, and G. W. Sybrecht Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension Circulation, September 11, 2001; 104(11): 1218 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
British Cardiac Society Guidelines and Medical Pra Recommendations on the management of pulmonary hypertension in clinical practice Heart, September 1, 2001; 86(90001): i1 - 13. [Full Text] [PDF]
|
|
|
|
|
|
M. A. KANDLER, K. von der HARDT, E. SCHOOF, J. DOTSCH, and W. RASCHER Persistent Improvement of Gas Exchange and Lung Mechanics by Aerosolized Perfluorocarbon Am. J. Respir. Crit. Care Med., July 1, 2001; 164(1): 31 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Galiè and A. Torbicki GENERAL CARDIOLOGY: Pulmonary arterial hypertension: new ideas and perspectives Heart, April 1, 2001; 85(4): 475 - 480. [Full Text]
|
|
|
|
 |
|
 S. Sharma, D. White, A. R. Imondi, M. E. Placke, D. M. Vail, and M. G. Kris Development of Inhalational Agents for Oncologic Use J. Clin. Oncol., March 15, 2001; 19(6): 1839 - 1847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ewert, R. Wensel, C. F. Opitz, M. M. Hoeper, E. Spiekerkoetter, and H. Fabel Aerosolized Iloprost for Primary Pulmonary Hypertension N. Engl. J. Med., November 9, 2000; 343(19): 1421 - 1422. [Full Text]
|
|
|
|
|
|
M. M. Hoeper, M. Schwarze, S. Ehlerding, A. Adler-Schuermeyer, E. Spiekerkoetter, J. Niedermeyer, M. Hamm, and H. Fabel Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue N. Engl. J. Med., June 22, 2000; 342(25): 1866 - 1870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 New Therapies for Pulmonary Hypertension Journal Watch (General), March 31, 2000; 2000(331): 9 - 9. [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
